Hookipa Pharma (NASDAQ:HOOK) Rating Increased to Buy at Zacks Investment Research

Share on StockTwits

Hookipa Pharma (NASDAQ:HOOK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday, Zacks.com reports. The firm presently has a $7.75 target price on the stock. Zacks Investment Research‘s price objective points to a potential upside of 10.87% from the stock’s previous close.

According to Zacks, “HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company. It is engaged in developing a class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform which is designed to reprogram the body’s immune system. HOOKIPA Pharma Inc. is based in New York, United States. “

A number of other brokerages have also recently commented on HOOK. Leerink Swann initiated coverage on shares of Hookipa Pharma in a research note on Monday, May 13th. They set an “outperform” rating and a $20.00 price target for the company. Royal Bank of Canada restated a “buy” rating and set a $23.00 price target on shares of Hookipa Pharma in a research note on Wednesday. Svb Leerink initiated coverage on shares of Hookipa Pharma in a research note on Monday, May 13th. They set an “outperform” rating and a $20.00 price target for the company. Finally, Bank of America initiated coverage on shares of Hookipa Pharma in a research note on Monday, May 13th. They set a “buy” rating and a $17.00 price target for the company. Five research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $17.55.

Shares of NASDAQ HOOK traded down $0.01 during mid-day trading on Thursday, hitting $6.99. The company had a trading volume of 17,294 shares, compared to its average volume of 113,503. The firm’s 50-day moving average price is $6.98. Hookipa Pharma has a 12 month low of $6.06 and a 12 month high of $14.76.

Hookipa Pharma (NASDAQ:HOOK) last released its earnings results on Monday, May 20th. The company reported ($9.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($8.85). The company had revenue of $2.24 million for the quarter, compared to analyst estimates of $0.50 million. On average, sell-side analysts predict that Hookipa Pharma will post -2.14 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new stake in shares of Hookipa Pharma during the second quarter worth approximately $40,000. Northern Trust Corp acquired a new stake in shares of Hookipa Pharma during the second quarter worth approximately $72,000. Morgan Stanley acquired a new stake in shares of Hookipa Pharma during the second quarter worth approximately $99,000. Vanguard Group Inc. acquired a new stake in shares of Hookipa Pharma during the second quarter worth approximately $538,000. Finally, BlackRock Inc. acquired a new stake in shares of Hookipa Pharma during the second quarter worth approximately $737,000.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Featured Story: How can you know how many shares are floating?

Get a free copy of the Zacks research report on Hookipa Pharma (HOOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.